Neal D. Shore, MD, FACS, presented “GRU Challenging Case: Androgen Deprivation Therapy” during the 30th Annual International Prostate Cancer Update on January 23rd, 2020 in Beaver Creek, Colorado.
How to cite: Shore, Neal D. “GRU Challenging Case: Androgen Deprivation Therapy” January 23rd, 2020. Accessed Dec 2024. https://dev.grandroundsinurology.com/case-1-androgen-deprivation-therapy/
GRU Challenging Case: Androgen Deprivation Therapy – Summary:
Neal D. Shore, MD, FACS, Medical Director for the Carolina Urologic Research Center and Atlantic Urology Clinics, leads a panel discussion the physiological and economic factors impacting the ADT selection process. Along with panelists Raoul Concepcion, MD, Michael Cookson, MD, Lawrence Karsh, MD, and Thomas Keane, MD, Dr. Shore emphasizes the impact of the current volume-based and economically incentivized model of treatment and how this can restrict urologists in terms of ADT options. They also discuss the physiological impacts of drug-drug interactions, alternate modes of administration, and the complex prospect of an oral alternative.
About The 30th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. Dr. Shore led this panel during the 30th iteration of the meeting in January 2020.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Neal D. Shore, MD, FACS, is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina.
Dr. Shore has conducted more than 350 clinical trials, focusing mainly on genitourinary oncology, and serves on the executive boards of the Society of Urologic Oncology and the Bladder Cancer Advocacy Network. He is Past President of the Large Urology Group Practice Association. He is a founder for both CUSP Clinical Trials Consortium and DASHKO, a national urology practice data registry. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee and the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank, and the Editorial Boards of Review in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, and World Journal of Urology. He serves as Editor of Everyday Urology-Oncology. Dr. Shore has written more than 200 peer-reviewed publications and numerous book chapters. He performs peer review for Lancet Oncology, New England Journal of Medicine, European Urology, the Journal of Urology, Urology, BJUI, PCPD, and numerous other high-impact scientific journals.
A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6-month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.
